Form 4: Akari Therapeutics Director Raymond Prudo-Chlebosz Reports Stock Option Grants

Director Raymond Prudo-Chlebosz reports acquisition of stock options and beneficial ownership of Akari Therapeutics shares.

Summary

• Raymond Prudo-Chlebosz, a director of Akari Therapeutics Plc, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of stock options to purchase 175,000 and 225,000 American Depositary Shares (ADS) representing Ordinary Shares of Akari Therapeutics on March 20, 2025.
• The exercise price for both stock option grants is $1.50.
• The options expire on March 20, 2035.
• The director also reported direct ownership of 2,484,990 ADSs and indirect ownership through Praxis Trustees Limited (19,355 ADSs) and RPC Pharma Limited (400,383 ADSs).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions and holdings.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the holdings and potential incentives of company directors.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding the holdings and potential incentives of a company director.

Key Dates

Keywords

Akari Therapeutics, Director, Stock Options, Beneficial Ownership, ADS, AKTX, Form 4